Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia

Alzheimer's and Dementia

Volumn 12, Issue 11, 2016, Pages 1149-1158

  Bereczki, Erika ^a   Francis, Paul T ^b   Howlett, David ^b   Pereira, Joana B ^a   Höglund, Kina ^a,c   Bogstedt, Anna ^d,e   Cedazo Minguez, Angel ^a   Baek, Jean Ha ^a   Hortobágyi, Tibor ^f   Attems, Johannes ^g   Ballard, Clive ^b   Aarsland, Dag ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

^e SCIENCE FOR LIFE LABORATORY   (Sweden)

^f UNIVERSITY OF DEBRECEN   (Hungary)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Alzheimer's disease; Cognitive impairment; Dementia with Lewy bodies; Neurogranin; Parkinson's disease with dementia; Rab3A; SNAP25; Synaptic dysfunction

Indexed keywords

NEUROGRANIN; NEUROGRANIN 1; RAB PROTEIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; NERVE PROTEIN;

AGED; ALZHEIMER DISEASE; ANTERIOR CINGULATE; ARTICLE; AUTOPSY; BRAIN ANALYSIS; BRAIN REGION; COGNITIVE DEFECT; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; FEMALE; HUMAN; HUMAN TISSUE; MALE; NEOCORTEX; NEUROPATHOLOGY; PARIETAL LOBE; PARKINSON DISEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SYNAPSE; TEMPORAL LOBE; VERY ELDERLY; BRAIN; COHORT ANALYSIS; DEMENTIA ASSESSMENT; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PSYCHOLOGY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOMARKERS; BRAIN; COGNITIVE DYSFUNCTION; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LEWY BODY DISEASE; MALE; MENTAL STATUS AND DEMENTIA TESTS; MULTIVARIATE ANALYSIS; NERVE TISSUE PROTEINS; SENSITIVITY AND SPECIFICITY; SYNAPSES;

EID: 84994422977     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.04.005     Document Type: Article

References (45)

1. [1] Kivipelto, M., Mangialasche, F., Alzheimer disease: To what extent can Alzheimer disease be prevented?. Nat Rev Neurol 10 (2014), 552–553.
2. [2] Kirvell, S.L., Esiri, M., Francis, P.T., Down-regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer's disease. J Neurochem 98 (2006), 939–950.
3. [3] McKeith, I.G., Galasko, D., Kosaka, K., Perry, E.K., Dickson, D.W., Hansen, L.A., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47 (1996), 1113–1124.
4. [4] Campbell, S., Stephens, S., Ballard, C., Dementia with Lewy bodies: clinical features and treatment. Drugs Aging 18 (2001), 397–407.
5. [5] McKeith, I.G., Dickson, D.W., Lowe, J., Emre, M., O'Brien, J.T., Feldman, H., et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65 (2005), 1863–1872.
6. [6] Howlett, D.R., Whitfield, D., Johnson, M., Attems, J., O'Brien, J.T., Aarsland, D., et al. Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias. Brain Pathol 25 (2015), 401–408.
7. [7] Wishart, T.M., Parson, S.H., Gillingwater, T.H., Synaptic vulnerability in neurodegenerative disease. J Neuropathol Exp Neurol 65 (2006), 733–739.
8. [8] Gottschall, P.E., Ajmo, J.M., Eakin, A.K., Howell, M.D., Mehta, H., Bailey, L.A., Panel of synaptic protein ELISAs for evaluating neurological phenotype. Exp Brain Res 201 (2010), 885–893.
9. [9] Walch-Solimena, C., Jahn, R., Sudhof, T.C., Synaptic vesicle proteins in exocytosis: what do we know?. Curr Opin Neurobiol 3 (1993), 329–336.
10. [10] Honer, W.G., Pathology of presynaptic proteins in Alzheimer's disease: more than simple loss of terminals. Neurobiol Aging 24 (2003), 1047–1062.
11. [11] Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., DeTeresa, R., Hill, R., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30 (1991), 572–580.
12. [12] Scheff, S.W., Price, D.A., Schmitt, F.A., DeKosky, S.T., Mufson, E.J., Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68 (2007), 1501–1508.
13. [13] Aarsland, D., Perry, R., Brown, A., Larsen, J.P., Ballard, C., Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 58 (2005), 773–776.
14. [14] Compta, Y., Parkkinen, L., O'Sullivan, S.S., Vandrovcova, J., Holton, J.L., Collins, C., et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain 134 (2011), 1493–1505.
15. [15] Pienaar, I.S., Burn, D., Morris, C., Dexter, D., Synaptic protein alterations in Parkinson's disease. Mol Neurobiol 45 (2012), 126–143.
16. [16] Mak, E., Su, L., Williams, G.B., Watson, R., Firbank, M., Blamire, A.M., et al. Longitudinal assessment of global and regional atrophy rates in Alzheimer's disease and dementia with Lewy bodies. Neuroimage Clin 7 (2015), 456–462.
17. [17] Oesterhus, R., Soennesyn, H., Rongve, A., Ballard, C., Aarsland, D., Vossius, C., Long-term mortality in a cohort of home-dwelling elderly with mild Alzheimer's disease and Lewy body dementia. Dement Geriatr Cogn Disord 38 (2014), 161–169.
18. [18] Williams, M.M., Xiong, C., Morris, J.C., Galvin, J.E., Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology 67 (2006), 1935–1941.
19. [19] Kramer, M.L., Schulz-Schaeffer, W.J., Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 27 (2007), 1405–1410.
20. [20] Baudier, J., Deloulme, J.C., Van Dorsselaer, A., Black, D., Matthes, H.W., Purification and characterization of a brain-specific protein kinase C substrate, neurogranin (p17). Identification of a consensus amino acid sequence between neurogranin and neuromodulin (GAP43) that corresponds to the protein kinase C phosphorylation site and the calmodulin-binding domain. J Biol Chem 266 (1991), 229–237.
21. [21] Hayashi, T., McMahon, H., Yamasaki, S., Binz, T., Hata, Y., Sudhof, T.C., et al. Synaptic vesicle membrane fusion complex: action of clostridial neurotoxins on assembly. EMBO J 13 (1994), 5051–5061.
22. [22] Kay, L., Humphreys, L., Eickholt, B.J., Burrone, J., Neuronal activity drives matching of pre- and postsynaptic function during synapse maturation. Nat Neurosci 14 (2011), 688–690.
23. [23] Folstein, M.F., Folstein, S.E., McHugh, P.R., “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975), 189–198.
24. [24] Davies, C.A., Mann, D.M., Sumpter, P.Q., Yates, P.O., A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci 78 (1987), 151–164.
25. [25] Terry, R.D., Cell death or synaptic loss in Alzheimer disease. J Neuropathol Exp Neurol 59 (2000), 1118–1119.
26. [26] Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L.A., McKeel, D.W. Jr., et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 56 (2001), 127–129.
27. [27] Cummings, D.M., Liu, W., Portelius, E., Bayram, S., Yasvoina, M., Ho, S.H., et al. First effects of rising amyloid-beta in transgenic mouse brain: synaptic transmission and gene expression. Brain 138 (2015), 1992–2004.
28. [28] Whitfield, D.R., Vallortigara, J., Alghamdi, A., Howlett, D., Hortobagyi, T., Johnson, M., et al. Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment. Neurobiol Aging 35 (2014), 2836–2844.
29. [29] Mukaetova-Ladinska, E.B., Andras, A., Milne, J., Abdel-All, Z., Borr, I., Jaros, E., et al. Synaptic proteins and choline acetyltransferase loss in visual cortex in dementia with Lewy bodies. J Neuropathol Exp Neurol 72 (2013), 53–60.
30. [30] Taylor, J.P., Firbank, M.J., He, J., Barnett, N., Pearce, S., Livingstone, A., et al. Visual cortex in dementia with Lewy bodies: magnetic resonance imaging study. Br J Psychiatry 200 (2012), 491–498.
31. [31] Ren, Y., Sahara, N., Characteristics of tau oligomers. Front Neurol, 4, 2013, 102.
32. [32] Spillantini, M.G., Goedert, M., Tau pathology and neurodegeneration. Lancet Neurol 12 (2013), 609–622.
33. [33] Kvartsberg, H., Duits, F.H., Ingelsson, M., Andreasen, N., Ohrfelt, A., Andersson, K., et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement 11 (2015), 1180–1190.
34. [34] Shinohara, M., Petersen, R.C., Dickson, D.W., Bu, G., Brain regional correlation of amyloid-beta with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-beta accumulation. Acta Neuropathol 125 (2013), 535–547.
35. [35] Shinohara, M., Fujioka, S., Murray, M.E., Wojtas, A., Baker, M., Rovelet-Lecrux, A., et al. Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease. Brain 137 (2014), 1533–1549.
36. [36] Spires-Jones, T.L., Hyman, B.T., The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron 82 (2014), 756–771.
37. [37] Pooler, A.M., Noble, W., Hanger, D.P., A role for tau at the synapse in Alzheimer's disease pathogenesis. Neuropharmacology 76 Pt A (2014), 1–8.
38. [38] Chen, R.H., Wislet-Gendebien, S., Samuel, F., Visanji, N.P., Zhang, G., Marsilio, D., et al. alpha-Synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity. J Biol Chem 288 (2013), 7438–7449.
39. [39] Dalfo, E., Barrachina, M., Rosa, J.L., Ambrosio, S., Ferrer, I., Abnormal alpha-synuclein interactions with rab3a and rabphilin in diffuse Lewy body disease. Neurobiol Dis 16 (2004), 92–97.
40. [40] Morrison, J.H., Baxter, M.G., The ageing cortical synapse: hallmarks and implications for cognitive decline. Nat Rev Neurosci 13 (2012), 240–250.
41. [41] Aarsland, D., Litvan, I., Salmon, D., Galasko, D., Wentzel-Larsen, T., Larsen, J.P., Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 74 (2003), 1215–1220.
42. [42] Tiraboschi, P., Salmon, D.P., Hansen, L.A., Hofstetter, R.C., Thal, L.J., Corey-Bloom, J., What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?. Brain 129 (2006), 729–735.
43. [43] Fuster, J.M., The prefrontal cortex–an update: time is of the essence. Neuron 30 (2001), 319–333.
44. [44] Brinkmalm, A., Brinkmalm, G., Honer, W.G., Frolich, L., Hausner, L., Minthon, L., et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. Mol Neurodegener, 9, 2014, 53.
45. [45] Hansen, L.A., Daniel, S.E., Wilcock, G.K., Love, S., Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer's disease and dementia. J Neurol Neurosurg Psychiatry 64 (1998), 653–656.